Syngene International Ltd
Syngene International Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Q3 FY'25 showed an 11% revenue growth after two quarters of decline, indicating a return to growth momentum. Syngene expects growth momentum to continue in Q4 FY'25, aiming for single-digit revenue growth for the full year. - Operating EBITDA margins are expected to recover to be around the high-20% range for the full year. - After initial delays, Q3 marked a return to growth with revenue up 11% and operating EBITDA margin at 30.1%. - Longer-term growth is supported by investments in capacity expansion, digitization, and automation. - The company is optimistic but cautious, focusing on executing strategies to capture China Plus One market shifts. - Stability in US biotech funding and improved client contract conversions underpin positive near-term outlook. - No formal multi-year earnings guidance given; short-term quarterly trajectory is improving. - CAPEX of approx.
From Syngene International Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Q3 FY'25 showed an 11% revenue growth after two quarters of decline, indicating a return to growth momentum.
- Momentum from the first half in RFPs continued into Q3 with no significant negative change despite geopolitical and regulatory uncertainties.
- The demand recovery, especially in US biotech funding, stabilized later than expected (delay of 8-12 weeks).
- The company expects single-digit revenue growth for the full year FY'25 and growth momentum to continue into Q4 FY'25.
- Initial pilot projects with large and mid-sized pharma are converting into longer-term contracts, supporting future revenue.
- Investment in capacity, especially in biologics (Unit-III facility), and capabilities is expected to fuel future growth.
2 more points from Syngene International Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Syngene International Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Syngene continues to invest in expansion of capacities and capabilities to drive long-term growth.
- CAPEX for the year remains on track at around $60 million by year-end.
- Approximately 50% of CAPEX in the first nine months was in research services, and about 25% in biologics (upgrading Unit-III manufacturing facility acquired from Stelis Biopharma).
- Investments are focused on digitization and automation to increase business efficiencies.
- Unit-III biologics facility renovation and retooling to be completed by April, with capacity ramp-up and selling cycle to follow.
2 more points from Syngene International Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Syngene International Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company experienced strong RFP (Request for Proposal) momentum in the first half of the year, which continued into Q3.
- Q3 revenue grew by 11%, following two quarters of 2% decline each.
- Initial pilot projects with large and mid-size pharma companies are converting into longer-term contracts.
- There is positive momentum particularly in the CDMO division led by biologics.
- The recovery in demand, particularly from US biotech funding, stabilized later than expected (8 to 12 weeks delay).
2 more points from Syngene International Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Syngene International Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.0K Cr, net profit ₹148 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Syngene International Ltd's management said in earlier quarters
- Q1 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q1 FY27 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Healthcare Services this season
- Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.
- 3B Blackbio DX Ltd (Q3 FY25)
Consolidated Revenue from Operations Q3 FY 2024-25: ₹2,539.25 Lakh vs ₹1,766.89 Lakh in Q3 FY 2023-24 (↑ approx. Key concall takeaways from 3B Blackbio DX…
- Rainbow Childrens Medicare Ltd (Q3 FY25)
Mature hospitals show approximately 9% inpatient (IP) volume growth on a like-to-like basis. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…
- Vijaya Diagnostic Centre Ltd (Q3 FY25)
Wellness segment growth remains strong, contributing about 14% to the top line, with potential seasonal Q4 benefits. Key concall takeaways from Vijaya…
Arthneeti Pro · Annual
Syngene International Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Syngene International Ltd Q3 FY25 results?
Q3 FY'25 showed an 11% revenue growth after two quarters of decline, indicating a return to growth momentum. Syngene expects growth momentum to continue in Q4 FY'25, aiming for single-digit revenue growth for the full year. - Operating EBITDA margins are expected to recover to be around the high-20% range for the full year. - After initial delays, Q3 marked a return to growth with revenue up 11% and operating EBITDA margin at 30.1%. - Longer-term growth is supported by investments in capacity expansion, digitization, and automation. - The company is optimistic but cautious, focusing on executing strategies to capture China Plus One market shifts. - Stability in US biotech funding and improved client contract conversions underpin positive near-term outlook. - No formal multi-year earnings guidance given; short-term quarterly trajectory is improving. - CAPEX of approx.
What is Syngene International Ltd share price analysis?
Syngene International Ltd currently shows a neutral. The stock trades at a P/E of 55.5 with a market cap of ₹16,427 Cr. Investors should review the full earnings analysis for detailed insights.
Is Syngene International Ltd planning capital expenditure?
Syngene continues to invest in expansion of capacities and capabilities to drive long-term growth.
Keep Syngene International Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.